$KIDS
ORTHOPEDIATRICS CORP Stock $kids

$kids Overview Financials Valuation SEC Filings Company Website

2021 Q2 Form 10-Q Financial Statement

#000142545021000120 Filed on August 05, 2021

Income Statement

Concept	2021 Q2	2020 Q2
Revenue	$26.70M	$13.59M
YoY Change	96.39%	-25.31%
Cost Of Revenue	$6.252M	$3.532M
YoY Change	77.01%	-22.9%
Gross Profit	$20.44M	$10.06M
YoY Change	103.19%	-26.13%
Gross Profit Margin	76.58%	74.02%
Selling, General & Admin	$21.96M	$16.20M
YoY Change	35.61%	14.26%
% of Gross Profit	107.44%	160.99%
Research & Development	$1.325M	$881.0K
YoY Change	50.4%	-28.61%
% of Gross Profit	6.48%	8.76%
Depreciation & Amortization	$2.607M	$1.910M
YoY Change	36.49%	76.85%
% of Gross Profit	12.75%	18.98%
Operating Expenses	$23.29M	$17.08M
YoY Change	36.37%	10.83%
Operating Profit	-$2.846M	-$7.017M
YoY Change	-59.44%	292.01%
Interest Expense	-$1.571M	-$2.310M
YoY Change	-31.99%	266.67%
% of Operating Profit
Other Income/Expense, Net	-$1.196M	-$2.430M
YoY Change	-50.78%	263.23%
Pretax Income	-$4.042M	-$9.447M
YoY Change	-57.21%	284.18%
Income Tax	-$286.0K	$0.00
% Of Pretax Income
Net Earnings	-$3.756M	-$9.447M
YoY Change	-60.24%	260.85%
Net Earnings / Revenue	-14.07%	-69.5%
Basic Earnings Per Share	-$0.19	-$0.54
Diluted Earnings Per Share	-$0.19	-$0.54
COMMON SHARES
Basic Shares Outstanding	19.28M shares	17.55M shares
Diluted Shares Outstanding	19.28M shares	17.55M shares

Balance Sheet

Concept	2021 Q2	2020 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$65.85M	$113.1M
YoY Change	-41.77%	416.44%
Cash & Equivalents	$10.57M	$113.1M
Short-Term Investments
Other Short-Term Assets	$3.842M	$2.900M
YoY Change	32.48%	-92.1%
Inventory	$56.38M	$48.88M
Prepaid Expenses
Receivables	$19.22M	$14.90M
Other Receivables	$95.00K	$700.0K
Total Short-Term Assets	$145.4M	$180.4M
YoY Change	-19.4%	68.82%
LONG-TERM ASSETS
Property, Plant & Equipment	$28.24M	$24.13M
YoY Change	17.04%	15.38%
Goodwill	$69.66M	$68.42M
YoY Change	1.81%	523.64%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$162.3M	$148.1M
YoY Change	9.56%	525.64%
TOTAL ASSETS
Total Short-Term Assets	$145.4M	$180.4M
Total Long-Term Assets	$162.3M	$148.1M
Total Assets	$307.7M	$328.5M
YoY Change	-6.34%	116.92%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$10.14M	$6.003M
YoY Change	68.95%	0.05%
Accrued Expenses	$5.651M	$4.500M
YoY Change	25.58%	12.5%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change		-100.0%
Long-Term Debt Due	$134.0K	$128.0K
YoY Change	4.69%	-99.58%
Total Short-Term Liabilities	$30.33M	$24.77M
YoY Change	22.44%	-41.28%
LONG-TERM LIABILITIES
Long-Term Debt	$977.0K	$21.02M
YoY Change	-95.35%	-0.45%
Other Long-Term Liabilities	$292.0K	$120.0K
YoY Change	143.33%	20.0%
Total Long-Term Liabilities	$55.73M	$61.26M
YoY Change	-9.03%	189.46%
TOTAL LIABILITIES
Total Short-Term Liabilities	$30.33M	$24.77M
Total Long-Term Liabilities	$55.73M	$61.26M
Total Liabilities	$86.05M	$86.03M
YoY Change	0.03%	35.8%
SHAREHOLDERS EQUITY
Retained Earnings	-$175.9M	-$143.2M
YoY Change	22.82%	18.62%
Common Stock	$5.000K	$5.000K
YoY Change	0.0%	25.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$221.6M	$242.5M
YoY Change
Total Liabilities & Shareholders Equity	$307.7M	$328.5M
YoY Change	-6.34%	116.92%

Cashflow Statement

Concept	2021 Q2	2020 Q2
OPERATING ACTIVITIES
Net Income	-$3.756M	-$9.447M
YoY Change	-60.24%	260.85%
Depreciation, Depletion And Amortization	$2.607M	$1.910M
YoY Change	36.49%	76.85%
Cash From Operating Activities	-$8.971M	-$7.750M
YoY Change	15.75%	11.67%
INVESTING ACTIVITIES
Capital Expenditures	-$1.722M	-$2.010M
YoY Change	-14.33%	-45.68%
Acquisitions
YoY Change
Other Investing Activities	$0.00	-$1.720M
YoY Change	-100.0%	-96.56%
Cash From Investing Activities	-$1.722M	-$3.730M
YoY Change	-53.83%	-93.05%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-32.00K	70.96M
YoY Change	-100.05%	136.06%
NET CHANGE
Cash From Operating Activities	-8.971M	-7.750M
Cash From Investing Activities	-1.722M	-3.730M
Cash From Financing Activities	-32.00K	70.96M
Net Change In Cash	-10.73M	59.48M
YoY Change	-118.03%	-294.63%
FREE CASH FLOW
Cash From Operating Activities	-$8.971M	-$7.750M
Capital Expenditures	-$1.722M	-$2.010M
Free Cash Flow	-$7.249M	-$5.740M
YoY Change	26.29%	77.16%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2021
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Amendment Flag AmendmentFlag	false
	dei	Entity Central Index Key EntityCentralIndexKey	0001425450
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2021-06-30
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-38242
	dei	Entity Registrant Name EntityRegistrantName	OrthoPediatrics Corp
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	26-1761833
	dei	Entity Address Address Line1 EntityAddressAddressLine1	2850 Frontier Drive
CY2021Q2	us-gaap	Short Term Investments ShortTermInvestments	55288000	USD
	dei	Entity Address City Or Town EntityAddressCityOrTown	Warsaw
	dei	Entity Address State Or Province EntityAddressStateOrProvince	IN
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	46582
	dei	City Area Code CityAreaCode	574
	dei	Local Phone Number LocalPhoneNumber	268-6379
	dei	Security12b Title Security12bTitle	Common Stock, $0.00025 par value per share
	dei	Trading Symbol TradingSymbol	KIDS
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
	dei	Entity Ex Transition Period EntityExTransitionPeriod	true
	dei	Entity Shell Company EntityShellCompany	false
CY2021Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	19672616	shares
CY2021Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	10565000	USD
CY2020Q4	us-gaap	Short Term Investments ShortTermInvestments	55141000	USD
CY2021Q2	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	372000	USD
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	28758000	USD
CY2021Q2	us-gaap	Restricted Cash Current RestrictedCashCurrent	1371000	USD
CY2020Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	1374000	USD
CY2020Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	433000	USD
CY2021Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	19222000	USD
CY2020Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	17212000	USD
CY2021Q2	us-gaap	Inventory Net InventoryNet	56376000	USD
CY2020Q4	us-gaap	Inventory Net InventoryNet	52989000	USD
CY2021Q2	us-gaap	Notes And Loans Receivable Net Current NotesAndLoansReceivableNetCurrent	95000	USD
CY2020Q4	us-gaap	Notes And Loans Receivable Net Current NotesAndLoansReceivableNetCurrent	337000	USD
CY2021Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2471000	USD
CY2020Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2618000	USD
CY2021Q2	us-gaap	Assets Current AssetsCurrent	145388000	USD
CY2020Q4	us-gaap	Assets Current AssetsCurrent	158429000	USD
CY2021Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	28242000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	27227000	USD
CY2021Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	50552000	USD
CY2020Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	50284000	USD
CY2021Q2	us-gaap	Goodwill Goodwill	69656000	USD
CY2020Q4	us-gaap	Goodwill Goodwill	70511000	USD
CY2021Q2	us-gaap	Indefinite Lived Intangible Assets Excluding Goodwill IndefiniteLivedIntangibleAssetsExcludingGoodwill	13817000	USD
CY2020Q4	us-gaap	Indefinite Lived Intangible Assets Excluding Goodwill IndefiniteLivedIntangibleAssetsExcludingGoodwill	13961000	USD
CY2021Q2	kids	Assets Noncurrent Excluding Property Plant And Equipment AssetsNoncurrentExcludingPropertyPlantAndEquipment	134025000	USD
CY2020Q4	kids	Assets Noncurrent Excluding Property Plant And Equipment AssetsNoncurrentExcludingPropertyPlantAndEquipment	134756000	USD
CY2021Q2	us-gaap	Assets Assets	307655000	USD
CY2020Q4	us-gaap	Assets Assets	320412000	USD
CY2021Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	10142000	USD
CY2020Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	10038000	USD
CY2021Q2	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	5651000	USD
CY2020Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	4540000	USD
CY2021Q2	us-gaap	Litigation Reserve Current LitigationReserveCurrent	0	USD
CY2020Q4	us-gaap	Litigation Reserve Current LitigationReserveCurrent	6342000	USD
CY2021Q2	kids	Long Term Debt Current Maturities Related Party LongTermDebtCurrentMaturitiesRelatedParty	134000	USD
CY2020Q4	kids	Long Term Debt Current Maturities Related Party LongTermDebtCurrentMaturitiesRelatedParty	131000	USD
CY2021Q2	kids	Business Combination Contingent Consideration Acquisition Installment Payable Current BusinessCombinationContingentConsiderationAcquisitionInstallmentPayableCurrent	12683000	USD
CY2020Q4	kids	Business Combination Contingent Consideration Acquisition Installment Payable Current BusinessCombinationContingentConsiderationAcquisitionInstallmentPayableCurrent	12233000	USD
CY2021Q2	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	1719000	USD
CY2020Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	1744000	USD
CY2021Q2	us-gaap	Liabilities Current LiabilitiesCurrent	30329000	USD
CY2020Q4	us-gaap	Liabilities Current LiabilitiesCurrent	35028000	USD
CY2021Q2	us-gaap	Long Term Notes And Loans LongTermNotesAndLoans	977000	USD
CY2020Q4	us-gaap	Long Term Notes And Loans LongTermNotesAndLoans	1044000	USD
CY2021Q2	kids	Business Combination Contingent Consideration Acquisition Installment Payable Noncurrent BusinessCombinationContingentConsiderationAcquisitionInstallmentPayableNoncurrent	13546000	USD
CY2020Q4	kids	Business Combination Contingent Consideration Acquisition Installment Payable Noncurrent BusinessCombinationContingentConsiderationAcquisitionInstallmentPayableNoncurrent	12784000	USD
CY2021Q2	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	35850000	USD
CY2020Q4	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	30710000	USD
CY2021Q2	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	5060000	USD
CY2020Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	5755000	USD
CY2021Q2	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	292000	USD
CY2020Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	323000	USD
CY2021Q2	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	55725000	USD
CY2020Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	50616000	USD
CY2021Q2	us-gaap	Liabilities Liabilities	86054000	USD
CY2020Q4	us-gaap	Liabilities Liabilities	85644000	USD
CY2020Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00025
CY2021Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00025
CY2021Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	50000000	shares
CY2020Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	50000000	shares
CY2021Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	19670044	shares
CY2021Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	19670044	shares
CY2020Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	19560291	shares
CY2020Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	19560291	shares
CY2021Q2	us-gaap	Common Stock Value CommonStockValue	5000	USD
CY2020Q4	us-gaap	Common Stock Value CommonStockValue	5000	USD
CY2021Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	391415000	USD
CY2020Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	388622000	USD
CY2021Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-175901000	USD
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-161766000	USD
CY2021Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	6082000	USD
CY2020Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	7907000	USD
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	221601000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	234768000	USD
CY2021Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	307655000	USD
CY2020Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	320412000	USD
CY2021Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	26695000	USD
CY2020Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	13593000	USD
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	48157000	USD
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	29949000	USD
CY2021Q2	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	6252000	USD
CY2020Q2	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	3532000	USD
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	11389000	USD
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	7675000	USD
CY2021Q2	us-gaap	Gross Profit GrossProfit	20443000	USD
CY2020Q2	us-gaap	Gross Profit GrossProfit	10061000	USD
	us-gaap	Gross Profit GrossProfit	36768000	USD
	us-gaap	Gross Profit GrossProfit	22274000	USD
CY2021Q2	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	10876000	USD
CY2020Q2	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	5620000	USD
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	19825000	USD
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	13184000	USD
CY2021Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	11088000	USD
CY2020Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	10577000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	23129000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	18458000	USD
CY2021Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1325000	USD
CY2020Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	881000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2633000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2146000	USD
CY2021Q2	us-gaap	Operating Expenses OperatingExpenses	23289000	USD
CY2020Q2	us-gaap	Operating Expenses OperatingExpenses	17078000	USD
	us-gaap	Operating Expenses OperatingExpenses	45587000	USD
	us-gaap	Operating Expenses OperatingExpenses	33788000	USD
CY2021Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-2846000	USD
CY2020Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-7017000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-8819000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-11514000	USD
CY2021Q2	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-581000	USD
CY2020Q2	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-1399000	USD
	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-1309000	USD
	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-1778000	USD
CY2021Q2	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	990000	USD
CY2020Q2	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	910000	USD
	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	5140000	USD
	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	910000	USD
CY2021Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	375000	USD
CY2020Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-121000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	535000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-190000	USD
CY2021Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-1196000	USD
CY2020Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-2430000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-5914000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-2878000	USD
CY2021Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-4042000	USD
CY2020Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-9447000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-14733000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-14392000	USD
CY2021Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-286000	USD
CY2020Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-598000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-3756000	USD
CY2020Q2	us-gaap	Net Income Loss NetIncomeLoss	-9447000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-14135000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-14392000	USD
CY2021Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	19275779	shares
CY2021Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	19275779	shares
CY2020Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	17549118	shares
CY2020Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	17549118	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	19263506	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	19263506	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	16986485	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	16986485	shares
CY2021Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.19
CY2021Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.19
CY2020Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.54
CY2020Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.54
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.73
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.73
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.85
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.85
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-3756000	USD
CY2020Q2	us-gaap	Net Income Loss NetIncomeLoss	-9447000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-14135000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-14392000	USD
CY2021Q2	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	1867000	USD
CY2020Q2	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	1522000	USD
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-1631000	USD
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	164000	USD
CY2021Q2	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	-70000	USD
CY2020Q2	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	0	USD
	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	-194000	USD
	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	0	USD
CY2021Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	1797000	USD
CY2020Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	1522000	USD
	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-1825000	USD
	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	164000	USD
CY2021Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-1959000	USD
CY2020Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-7925000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-15960000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-14228000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	234768000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-10379000	USD
CY2021Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-3622000	USD
CY2021Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	62000	USD
CY2021Q1	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	1316000	USD
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	222145000	USD
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-3756000	USD
CY2021Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	1797000	USD
CY2021Q2	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	1415000	USD
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	221601000	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	142361000	USD
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	-4945000	USD
CY2020Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-1358000	USD
CY2020Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	688000	USD
CY2020Q1	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	958000	USD
CY2020Q1	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	1750000	USD
CY2020Q1	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	187000	USD
CY2020Q1	us-gaap	Stockholders Equity StockholdersEquity	139267000	USD
CY2020Q2	us-gaap	Net Income Loss NetIncomeLoss	-9447000	USD
CY2020Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	1522000	USD
CY2020Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	593000	USD
CY2020Q2	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	2495000	USD
CY2020Q2	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	37638000	USD
CY2020Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	70394000	USD
CY2020Q2	us-gaap	Stockholders Equity StockholdersEquity	242462000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-14135000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-14392000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	5147000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	3285000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	2731000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	3453000	USD
	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	5140000	USD
	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	910000	USD
	kids	Business Combination Contingent Consideration Change In Fair Value Acquisition Installment Payable BusinessCombinationContingentConsiderationChangeInFairValueAcquisitionInstallmentPayable	1212000	USD
	kids	Business Combination Contingent Consideration Change In Fair Value Acquisition Installment Payable BusinessCombinationContingentConsiderationChangeInFairValueAcquisitionInstallmentPayable	886000	USD
	us-gaap	Increase Decrease In Deferred Income Taxes IncreaseDecreaseInDeferredIncomeTaxes	602000	USD
	us-gaap	Increase Decrease In Deferred Income Taxes IncreaseDecreaseInDeferredIncomeTaxes	0	USD
	us-gaap	Increase Decrease In Accounts And Notes Receivable IncreaseDecreaseInAccountsAndNotesReceivable	1781000	USD
	us-gaap	Increase Decrease In Accounts And Notes Receivable IncreaseDecreaseInAccountsAndNotesReceivable	-1609000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	3297000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	9599000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-106000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-66000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	191000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-746000	USD
	kids	Increase Decrease In Settlement Liabilities Current IncreaseDecreaseInSettlementLiabilitiesCurrent	6342000	USD
	kids	Increase Decrease In Settlement Liabilities Current IncreaseDecreaseInSettlementLiabilitiesCurrent	0	USD
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	1080000	USD
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-129000	USD
	us-gaap	Increase Decrease In Other Operating Capital Net IncreaseDecreaseInOtherOperatingCapitalNet	341000	USD
	us-gaap	Increase Decrease In Other Operating Capital Net IncreaseDecreaseInOtherOperatingCapitalNet	50000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-10891000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-14707000	USD
	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	0	USD
	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	1670000	USD
	us-gaap	Payments To Acquire Business Two Net Of Cash Acquired PaymentsToAcquireBusinessTwoNetOfCashAcquired	0	USD
	us-gaap	Payments To Acquire Business Two Net Of Cash Acquired PaymentsToAcquireBusinessTwoNetOfCashAcquired	1723000	USD
	us-gaap	Payments To Acquire Business Three Net Of Cash Acquired PaymentsToAcquireBusinessThreeNetOfCashAcquired	0	USD
	us-gaap	Payments To Acquire Business Three Net Of Cash Acquired PaymentsToAcquireBusinessThreeNetOfCashAcquired	796000	USD
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	2858000	USD
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	0	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	4474000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	5160000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-7332000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-9349000	USD
	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	0	USD
	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	5000000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	70207000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	62000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	1281000	USD
	us-gaap	Repayments Of Secured Debt RepaymentsOfSecuredDebt	64000	USD
	us-gaap	Repayments Of Secured Debt RepaymentsOfSecuredDebt	61000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-2000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	66427000	USD
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	29000	USD
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	17000	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-18196000	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	42388000	USD
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value Including Discontinued Operations CashAndCashEquivalentsAtCarryingValueIncludingDiscontinuedOperations	30132000	USD
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value Including Discontinued Operations CashAndCashEquivalentsAtCarryingValueIncludingDiscontinuedOperations	72027000	USD
CY2021Q2	us-gaap	Cash And Cash Equivalents At Carrying Value Including Discontinued Operations CashAndCashEquivalentsAtCarryingValueIncludingDiscontinuedOperations	11936000	USD
CY2020Q2	us-gaap	Cash And Cash Equivalents At Carrying Value Including Discontinued Operations CashAndCashEquivalentsAtCarryingValueIncludingDiscontinuedOperations	114415000	USD
	us-gaap	Interest Paid Net InterestPaidNet	29000	USD
	us-gaap	Interest Paid Net InterestPaidNet	513000	USD
	kids	Transfer Of Property And Equipment To Inventory TransferOfPropertyAndEquipmentToInventory	330000	USD
	kids	Transfer Of Property And Equipment To Inventory TransferOfPropertyAndEquipmentToInventory	229000	USD
	us-gaap	Nature Of Operations NatureOfOperations	BUSINESS<div style="padding-right:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:121%">OrthoPediatrics Corp., a Delaware corporation, is a medical device company committed to designing, developing and marketing anatomically appropriate implants and devices for children with orthopedic conditions, giving pediatric orthopedic surgeons and caregivers the ability to treat children with technologies specifically designed to meet their needs. We sell our specialized products, including PediLoc</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:121%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:121%">, PediPlates</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:121%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:121%">, Cannulated Screws, PediFlex</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.22pt;font-weight:400;line-height:121%;position:relative;top:-2.27pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:121%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:121%">nail, PediNail</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.22pt;font-weight:400;line-height:121%;position:relative;top:-2.27pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:121%">, PediLoc</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:121%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:121%"> Tibia, ACL Reconstruction System, Locking Cannulated Blade, Locking Proximal Femur, Spica Tables, RESPONSE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.22pt;font-weight:400;line-height:121%;position:relative;top:-2.27pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:121%"> Spine, BandLoc</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.22pt;font-weight:400;line-height:121%;position:relative;top:-2.27pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:121%">, Pediguard, Pediatric Nailing Platform \| Femur, Orthex</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:121%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:121%">, QuickPack</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:121%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.22pt;font-weight:400;line-height:121%;position:relative;top:-2.27pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:121%"> and ApiFix</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:121%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:121%"> Mid-C System, to various hospitals and medical facilities throughout the United States and various international markets. We currently use a contract manufacturing model for the manufacturing of implants and related surgical instrumentation. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">The Company began selling its products in the United States in 2008 and internationally in 2011. In 2017, we expanded operations and established legal entities in the United Kingdom, Australia and New Zealand, permitting us to sell under an agency model direct to local hospitals in these countries. We began selling direct to Canada in September 2018, Belgium and the Netherlands in January 2019, Italy in March 2020 and Germany, Switzerland and Austria in January 2021. Additionally, in March 2019, we established an operating company in the Netherlands in order to enhance our operations in Europe. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 4, 2019, we purchased all the issued and outstanding shares of stock of Vilex in Tennessee, Inc. ("Vilex") and all the issued and outstanding units of membership interests in Orthex, LLC ("Orthex") for $60,000 in total consideration. Vilex and Orthex are primarily manufacturers of foot and ankle surgical implants, including cannulated screws, fusion devices, surgical staples and bone plates, as well as Orthex Hexapod technology which is used to treat pediatric congenital deformities and limb length discrepancies.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 31, 2019, we divested substantially all of the assets relating to Vilex's adult product offerings to a wholly-owned subsidiary of Squadron Capital LLC ("Squadron") in exchange for a $25,000 reduction in a Term Note owed to Squadron in connection with the initial acquisition. As part of the sale, we also executed an exclusive license arrangement with Squadron providing for perpetual access to certain intellectual property and a mutual distribution agreement. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 9, 2020, we purchased all the issued and outstanding membership interest of Telos Partners, LLC ("Telos") for $3,300 in total consideration. Telos is a boutique regulatory consulting firm formed in Colorado. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 1, 2020, we purchased all the issued and outstanding membership interest of ApiFix, Ltd. ("ApiFix") for (a) $2,000 in cash, and (b) 934,783 shares of the Company's common stock, $0.00025 par value per share, representing approximately $35,000 (based on a closing share price of $37.63 on April 1, 2020. ApiFix, a corporation organized under the laws of Israel, has developed a minimally invasive deformity correction system for patients with Adolescent Idiopathic Scoliosis ("ApiFix System"). In addition, we have also agreed to pay as part of the purchase price the following anniversary payments, subject to certain limitations and adjustments: (i) approximately $13,000 on the second anniversary of the closing date, provided that such payment will be paid earlier if 150 clinical procedures using the ApiFix System are completed in the United States before such anniversary date, (ii) $8,000 on the third anniversary of the closing date; and (iii) $9,000 on the fourth anniversary of the closing date. In addition, to the extent that the product of our revenues from the ApiFix System for the twelve months ended June 30, 2024 multiplied by 2.25 exceeds the anniversary payments actually made for the third and fourth </span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">years, we have agreed to pay the selling shareholders a system sales payment in the amount of such excess. The anniversary payments and system sales payment may each be made in cash or cash and common stock (refer to Note 3). </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 10, 2020, we purchased certain intellectual property assets from Band-Lok, LLC, a North Carolina limited liability company ("Band-Lok"), related to its Tether Clamp and Implantation System ("Tether Clamp System") for approximately $3,400 in total consideration. We use the Tether Clamp System in connection with our Bandloc 5.5/6.0 System. We were previously the sole licensee of the purchased assets under a license agreement with Band-Lok. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our largest investor is Squadron, a private investment firm based in Granby, Connecticut. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The global COVID-19 pandemic (“COVID-19” or the “pandemic”), together with the preventative and precautionary measures taken by governments, governmental agencies, communities, businesses and hospital administrators, has impacted, and may continue to impact significant aspects of our business, including demand for our products, supply chain and distribution systems, our operations generally, and the timing for bringing new products to market. We also expect medical procedure rates to continue to vary by type and country, and could be impacted by regional COVID-19 case volumes, hospital and clinical occupancy and staffing levels, the willingness of patients to schedule elective procedures, travel and quarantine restrictions, vaccine immunization rates, and new COVID-19 variants. While COVID-19 case volumes appear to be decreasing in the U.S. and certain other countries as a result of higher vaccination rates, the global COVID-19 outlook remains uncertain as vaccination rates have slowed and the spread of new variants has accelerated. While the impact of COVID-19 has had, and may continue to have, an adverse effect on our business, results of operations, financial condition and cash flows, the nature and extent of such impact is unknown, as we cannot predict with confidence the ultimate duration or further severity of the pandemic.</span></div>
CY2021Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-175901000	USD
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-161766000	USD
	us-gaap	Use Of Estimates UseOfEstimates	Use of EstimatesPreparation of the condensed consolidated financial statements requires the use of estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, as of the date of the condensed consolidated financial statements. By their nature, these judgments are subject to an inherent degree of uncertainty. The impact of the coronavirus disease ("COVID-19") has significantly increased economic and demand uncertainty. We use historical experience and other assumptions as the basis for our judgments and estimates. Because future events and their effects cannot be determined with precision, actual results could differ significantly from these estimates. Any changes in these estimates will be reflected in the condensed consolidated financial statements.
CY2020Q4	us-gaap	Escrow Deposit EscrowDeposit	1250000	USD
CY2021Q2	us-gaap	Escrow Deposit EscrowDeposit	1250000	USD
CY2021Q2	us-gaap	Restricted Cash Current RestrictedCashCurrent	100000	EUR
	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	910000	USD
	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	0	USD
CY2020Q2	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	0	USD
CY2021Q2	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	0	USD
	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	0	USD
CY2021Q2	us-gaap	Impairment Of Intangible Assets Indefinitelived Excluding Goodwill ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill	0	USD
	us-gaap	Impairment Of Intangible Assets Indefinitelived Excluding Goodwill ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill	0	USD
CY2020Q2	us-gaap	Impairment Of Intangible Assets Indefinitelived Excluding Goodwill ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill	0	USD
	us-gaap	Impairment Of Intangible Assets Indefinitelived Excluding Goodwill ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill	0	USD
CY2021Q2	kids	Business Combination Contingent Consideration Change In Fair Value Acquisition Installment Payable BusinessCombinationContingentConsiderationChangeInFairValueAcquisitionInstallmentPayable	569000	USD
	kids	Business Combination Contingent Consideration Change In Fair Value Acquisition Installment Payable BusinessCombinationContingentConsiderationChangeInFairValueAcquisitionInstallmentPayable	1212000	USD
CY2020Q2	kids	Business Combination Contingent Consideration Change In Fair Value Acquisition Installment Payable BusinessCombinationContingentConsiderationChangeInFairValueAcquisitionInstallmentPayable	886000	USD
	kids	Business Combination Contingent Consideration Change In Fair Value Acquisition Installment Payable BusinessCombinationContingentConsiderationChangeInFairValueAcquisitionInstallmentPayable	886000	USD
CY2021Q2	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	990000	USD
	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	5140000	USD
CY2020Q2	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	910000	USD
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	0	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	0	shares
CY2020Q4	us-gaap	Goodwill Goodwill	70511000	USD
	us-gaap	Goodwill Foreign Currency Translation Gain Loss GoodwillForeignCurrencyTranslationGainLoss	-855000	USD
CY2021Q2	us-gaap	Goodwill Goodwill	69656000	USD
CY2021Q2	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	57441000	USD
CY2021Q2	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	6889000	USD
CY2021Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	50552000	USD
CY2020Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	55118000	USD
CY2020Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	4834000	USD
CY2020Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	50284000	USD
CY2021Q2	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	990000	USD
	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	5140000	USD
CY2021Q2	kids	Business Combination Contingent Consideration Change In Fair Value Acquisition Installment Payable BusinessCombinationContingentConsiderationChangeInFairValueAcquisitionInstallmentPayable	569000	USD
	kids	Business Combination Contingent Consideration Change In Fair Value Acquisition Installment Payable BusinessCombinationContingentConsiderationChangeInFairValueAcquisitionInstallmentPayable	1212000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-598000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2021Q2	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.040
CY2020Q2	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0
CY2020Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	16905000	USD
CY2020Q4	us-gaap	Tax Credit Carryforward Amount TaxCreditCarryforwardAmount	176000	USD
CY2014Q2	kids	Operating Loss Carryforwards Limitations On Use Estimated Amount Subject To Limitation OperatingLossCarryforwardsLimitationsOnUseEstimatedAmountSubjectToLimitation	16200000	USD
CY2014Q2	kids	Operating Loss Carryforwards Limitations On Use Estimated Amount Subject To Limitation Annual Limit OperatingLossCarryforwardsLimitationsOnUseEstimatedAmountSubjectToLimitationAnnualLimit	1062000	USD
CY2018Q4	kids	Operating Loss Carryforwards Limitations On Use Estimated Amount Subject To Limitation Annual Limit OperatingLossCarryforwardsLimitationsOnUseEstimatedAmountSubjectToLimitationAnnualLimit	9736000	USD
CY2018Q4	kids	Operating Loss Carryforwards Limitationson Use Estimated Amount Subject To Limitation Annual Limit Increase OperatingLossCarryforwardsLimitationsonUseEstimatedAmountSubjectToLimitationAnnualLimitIncrease	22430000	USD
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	0	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	0	shares
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-3756000	USD
CY2020Q2	us-gaap	Net Income Loss NetIncomeLoss	-9447000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-14135000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-14392000	USD
CY2021Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	19275779	shares
CY2021Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	19275779	shares
CY2020Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	17549118	shares
CY2020Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	17549118	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	19263506	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	19263506	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	16986485	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	16986485	shares
CY2021Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.19
CY2021Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.19
CY2020Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.54
CY2020Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.54
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.73
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.73
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.85
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.85
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	392449	shares
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	29949000	USD
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	467009	shares
	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1	segment
	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2021Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	26695000	USD
CY2020Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	13593000	USD
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	48157000	USD
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	29949000	USD
CY2021Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	26695000	USD
CY2020Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	13593000	USD
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	48157000	USD
	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent DefinedContributionPlanEmployerMatchingContributionPercent	0.04
CY2021Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	292000	USD
CY2021Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	295000	USD

Files In Submission

Name	View Source	Status
0001425450-21-000120-index-headers.html	Edgar Link	pending
0001425450-21-000120-index.html	Edgar Link	pending
0001425450-21-000120.txt	Edgar Link	pending
0001425450-21-000120-xbrl.zip	Edgar Link	pending
exhibit311-ceocertificatio.htm	Edgar Link	pending
exhibit312-cfocertificatio.htm	Edgar Link	pending
exhibit321-ceocertificatio.htm	Edgar Link	pending
exhibit322-cfocertificatio.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
kids-20210630.htm	Edgar Link	pending
kids-20210630.xsd	Edgar Link	pending
kids-20210630_cal.xml	Edgar Link	unprocessable
kids-20210630_def.xml	Edgar Link	unprocessable
kids-20210630_htm.xml	Edgar Link	completed
kids-20210630_lab.xml	Edgar Link	unprocessable
kids-20210630_pre.xml	Edgar Link	unprocessable
kidsnon-employeedirectorco.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$KIDS
ORTHOPEDIATRICS CORP Stock $kids

2021 Q2 Form 10-Q Financial Statement

#000142545021000120 Filed on August 05, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$KIDS ORTHOPEDIATRICS CORP Stock $kids

2021 Q2 Form 10-Q Financial Statement

#000142545021000120 Filed on August 05, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$KIDS
ORTHOPEDIATRICS CORP Stock $kids